Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status

The patent covers treatment with an immunotherapy that targets a neoantigen predicted to be presented by a human leukocyte antigen (HLA) allele that has not been lost in a tumor, where loss of HLA alleles is determined using a proprietary sequence-based method. The patent is not limited in terms of the type of immunotherapy used to target the neoantigen, and covers vaccine, cell therapy and antibody modalities.